Assessment of Adrenal Functions in Patients With Autosomal Dominant Polycystic Kidney Disease
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 49
- 试验地点
- 1
- 主要终点
- Inadequate response to tetracosactin infusion
研究概览
简要总结
We aimed to evaluate the hypothalamus-pituitary-adrenal axis in autosomal dominant polycystic kidney disease (ADPKD) patients. Twenty two ADPKD patients and 27 healthy subjects were enrolled.
详细描述
CONTEXT: Autosomal dominant polycystic kidney disease (ADPKD) is the most common hereditary kidney disease and extrarenal manifestations may be observed in many organ systems. Hypothalamus-pituitary-adrenal axis in patients with ADPKD was not evaluated extensively.
OBJECTIVE
We aimed to evaluate the hypothalamus-pituitary-adrenal axis in ADPKD patients.
METHODS: Twenty two ADPKD patients and 27 healthy subjects were enrolled. Basal dehydroepiandrosterone-sulfate (DHEAS) levels and cortisol and dehydroepiandrosterone responses to low dose short adrenocorticotropin stimulation test were assessed. Correlation analyses of these parameters with glomerular filtration rates, renal volumes and pain characteristics in patients with ADPKD were done.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Parallel
- 主要目的
- Diagnostic
- 盲法
- None
入排标准
- 年龄范围
- 20 Years 至 56 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Healthy subjects
- •Diagnosis of autosomal dominant polycystic kidney disease
排除标准
- •A glomerular filtration rate below 60 ml/min
- •History of recent major surgery
- •Systemic infections with fever
- •Significant hirsutism (Ferriman Gallwey score≥8)
- •Congenital adrenal hyperplasia
- •Late onset congenital adrenal hyperplasia
- •Systemic corticosteroid use (including previous use)
- •Topical corticosteroid use
- •Menstrual irregularity
- •History of thromboembolism
- •Uncontrolled diabetes or hypertension
- •History of psychosis
- •Pregnancy
- •Lactation
- •History of hypersensitivity to tetracosactin
研究组 & 干预措施
1
Patients with autosomal dominant polycystic kidney disease
干预措施: Tetracosactin (Drug)
2
Healthy subjects
干预措施: Tetracosactin (Drug)
结局指标
主要结局
Inadequate response to tetracosactin infusion
时间窗: 30 and 60 minutes after the drug is administered
次要结局
未报告次要终点